Kimberly-Clark Beats Estimates Despite China Sales Drag
The consumer goods maker reported higher third-quarter adjusted earnings even as organic sales slipped amid social media claims in China.
Updated on Nov. 5, 2026 in Consumer Goods
Live Poll
Do you trust major consumer brands to keep their everyday products safe?
Kimberly-Clark reported third-quarter adjusted earnings of $1.70 per share, up 17.2% from a year earlier and above the $1.65 analysts expected. Net sales fell 0.4% to $4.1 billion as organic sales declined 1.3%.
Why it matters
The China social media disruption, which spread claims that formamide was present in the company's diapers, weighed on sales during the quarter. The company reduced its organic sales growth outlook in August but kept its full-year 2026 outlook.
Adjusted gross margin was 35.5%, down 130 basis points from a year earlier, while International Personal Care segment operating profit fell 32.7% to $144 million. Diluted EPS of $5.37 reflected a pre-tax gain of about $1.4 billion from completing the Suzano transaction.
The players
Kimberly-Clark
A global consumer goods company known for brands such as Kleenex and Huggies, which reports results across personal care and family care categories.
Kenvue
The consumer health company behind Tylenol, acquired by Kimberly-Clark in a deal that expands its portfolio of household brands.
Suzano
A Brazilian pulp and paper producer that completed a transaction with Kimberly-Clark for its International Family Care and Professional business.
The details
Kimberly-Clark's International Personal Care organic sales fell 4.6%, including a roughly 770 basis point China headwind, while North America organic sales rose 0.4%. The company closed its International Family Care and Professional business transaction with Suzano on July 1 and acquired Kenvue, maker of Tylenol, on Nov. 2.
Timeline
August: Reduced organic sales growth outlook after China social media claims
July 1: Suzano International Family Care and Professional transaction closed
October: Weighed a bond offering to finance the Kenvue takeover
Nov. 2: Acquired Kenvue, maker of Tylenol
Market Landscape
The quarter's results come as Kimberly-Clark closes its Kenvue acquisition, expanding into health-adjacent brands like Tylenol. Its China exposure shows how reputational disruption on social media can quickly reduce sales in a single market.
Shoppers buying Kleenex, Huggies, or Tylenol may see shifts in product availability as the Kenvue acquisition integrates into Kimberly-Clark's portfolio. The company's full-year outlook suggests prices and product lines are expected to remain largely stable in 2026.
The takeaway
Kimberly-Clark's results show that a single market's social media controversy can outweigh strong performance elsewhere, making reputation management a material financial risk. Investors and consumers alike should watch whether the China disruption fades as the company integrates Kenvue.
Further reading
For more on how brand reputation and market shifts affect the sector, see Consumer Goods.
Live Poll
Do you trust major consumer brands to keep their everyday products safe?
